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Abstract
Background: Tumour regression observed in many conditional mouse models following
oncogene inactivation provides the impetus to develop, and a platform to preclinically evaluate,
novel therapeutics to inactivate specific oncogenes. Inactivating single oncogenes, such as c-Myc,
can reverse even advanced tumours. Intriguingly, transient c-Myc inactivation proved sufficient for
sustained osteosarcoma regression; the resulting osteocyte differentiation potentially explaining
loss of c-Myc's oncogenic properties. But would this apply to other tumours?
Results: We show that brief inactivation of c-Myc does not sustain tumour regression in two
distinct tissue types; tumour cells in pancreatic islets and skin epidermis continue to avoid apoptosis
after c-Myc reactivation, by virtue of Bcl-xL over-expression or a favourable microenvironment,
respectively. Moreover, tumours progress despite reacquiring a differentiated phenotype and
partial loss of vasculature during c-Myc inactivation. Interestingly, reactivating c-Myc in β-cell
tumours appears to result not only in further growth of the tumour, but also re-expansion of the
accompanying angiogenesis and more pronounced β-cell invasion (adenocarcinoma).
Conclusions: Given that transient c-Myc inactivation could under some circumstances produce
sustained tumour regression, the possible application of this potentially less toxic strategy in
treating other tumours has been suggested. We show that brief inactivation of c-Myc fails to sustain
tumour regression in two distinct models of tumourigenesis: pancreatic islets and skin epidermis.
These findings challenge the potential for cancer therapies aimed at transient oncogene
inactivation, at least under those circumstances where tumour cell differentiation and alteration of
epigenetic context fail to reinstate apoptosis. Together, these results suggest that treatment
schedules will need to be informed by knowledge of the molecular basis and environmental context
of any given cancer.
Background
Various mouse models of tumourigenesis have been
established using conditional systems to either induce or
knockout particular genes (oncogenes and tumour
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dependent manner. The ability to switch expression of a
given oncogene 'on' or 'off' in vivo has provided insight
into the mechanisms by which certain oncogenes can ini-
tiate tumourigenesis either alone or in combination with
other genetic lesions, and importantly, whether inactiva-
tion of the initiating oncogene is sufficient to cause
tumour regression (reviewed in: [1,2]). Given the impor-
tance of oncogene activation in human cancers, specific
targeting of oncogenic pathways provides a potentially
effective therapeutic strategy. For example, targeting of the
HER2/Neu receptor tyrosine kinase (which is overex-
pressed in up to 30% of primary human breast cancers)
with the neutralizing antibody Trastuzumab has been
used successfully in clinical trials, in combination with
other agents, to slow disease progression (refs in [3]). Sim-
ilarly, patients with chronic myelogenous leukaemia
(CML) have been effectively treated with the ABL kinase
inhibitor, Imatinib (Gleevec), inducing clinical remission
whilst in the CML phase [4,5].
Several studies using conditional mouse models of vari-
ous cancers have unexpectedly shown that inactivation of
the initiating oncogene is sufficient for reversal not only of
the primary tumour but also of invasive and metastatic
lesions, many of which contain multiple genetic and epi-
genetic alterations [6-18].
The tumour regression observed in many of these models
following sustained oncogene inactivation provides a
powerful platform on which to build a deeper under-
standing of fundamental tumour biology and with which
to preclinically evaluate novel therapeutics to target spe-
cific genes. A recent study has shown that brief inactiva-
tion (10 days) of c-Myc was sufficient for the sustained
regression of c-Myc induced invasive osteogenic sarcomas
in transgenic mice [19]; subsequent re-activation of c-Myc
led to extensive apoptosis rather than restoration of the
neoplastic phenotype. Possible explanations for this out-
come include changes in epigenetic context that may have
occurred within the cell type, that is, presumably between
the immature cell in which c-Myc was originally activated
and the more differentiated cell resulting from subsequent
(brief) inactivation of c-Myc. In this tumour model,
although c-Myc expression is initiated in immature oste-
oblasts during embryogenesis, subsequent inactivation of
c-Myc in osteogenic sarcoma cells induces differentiation
into mature osteocytes. Therefore, re-activation of c-Myc
now takes place in a different cellular context and induces
apoptosis rather than neoplastic progression. However,
irrespective of the actual underlying mechanisms, these
intriguing findings suggest the novel possibility of
employing transient inactivation of c-Myc as a therapeutic
strategy in certain cancers, thus limiting potential toxic
effects resulting from prolonged therapeutic inactivation
[1,2]. In fact, there is widespread interest in determining
the optimal timing of existing therapies, including trials of
pulsatile or 'metronomic' chemotherapy regimens in var-
ious cancers. Self-evidently, therefore, it was essential to
determine if this phenomenon was unique to this mouse
model or if sustained regression of tumours originating in
different tissues and under differing circumstances could
also be induced by transient c-Myc inactivation.
Previously, we have shown that sustained c-Myc inactiva-
tion in locally invasive pancreatic islet tumours (induced
by c-Myc activation in β-cells on a background of Bcl-xL
overexpression) induced β-cell growth arrest and re-differ-
entiation into mature β-cells, accompanied by the col-
lapse of tumour vasculature and tumour cell mass
resulting from apoptosis, despite the constitutive expres-
sion of Bcl-xL in the tumour cells [9]. Similarly, in pre-
malignant skin epidermal tumours (papillomatosis)
induced following activation of c-Myc alone, skin lesions
completely regressed within 4 weeks after sustained inac-
tivation of c-Myc [8]. However, given the continual out-
ward migration and shedding of growth-arrested and re-
differentiated keratinocytes from the skin surface, it was
not established whether this action alone was responsible
for the removal of skin tumour cells or if apoptosis also
played a part.
These conditional models, in which c-Myc-induced
tumours of pancreatic islets and skin epidermis can be ini-
tiated at any given time in the adult animal, were chosen
for the studies presented here and offer several advantages
(reviewed in [20]). First, tumourigenesis after c-Myc acti-
vation is initiated and proceeds by different routes, with
inherent pro-apoptotic activity avoided by an additional
genetic alteration (expression of the anti-apoptotic pro-
tein, BclxL) as is the case in the islet tumourigenesis
model, or by the presence of survival cues in the microen-
vironment, as seen in c-Myc-induced skin tumours. Sec-
ond, we already know that sustained c-Myc inactivation
leads to regression in both cases.
Here we show the consequences of inactivating c-Myc
transiently, for a period of 4 to 9 days, in these distinct
tumour types in vivo. In contrast to the osteogenic sarcoma
model, re-activating c-Myc in islet tumours does not lead
to accelerated β-cell apoptosis, but rather restores the
oncogenic properties of c-Myc, rapidly re-initiating β-cell
proliferation, loss of differentiation, loss of E-cadherin,
local invasion and angiogenesis. This occurs despite the
re-differentiation of previously c-Myc-activated tumour
cells to a more mature phenotype and the loss of some of
the newly acquired vasculature, occurring during the
period of c-Myc inactivation. Moreover, as no new β-cells
arise during the period of c-Myc inactivation, replication
is probably restored in those same cells that havePage 2 of 14
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dermis, reactivating c-Myc in suprabasal keratinocytes
does not result in apoptosis, which remains confined to
the shedding areas of parakeratosis at the skin surface, but
restores the papillomatous phenotype, inducing cell pro-
liferation and dysplasia. These results are in line with a
very recent study in a different system, published while
this manuscript was under consideration. Shachaf and
colleagues demonstrated that invasive c-Myc-induced
hepatocellular carcinomas regress when c-Myc expression
is turned off but, interestingly, some tumour cells remain
'dormant' even for prolonged periods and contribute to
cancer progression if c-Myc expression is subsequently
reinitiated [21].
Taken together, these findings suggest that a cautious
approach is required in considering cancer therapies
aimed at transient oncogene inactivation. First, a more
comprehensive understanding of the genetic basis and
environmental context of any individual tumour would
be required in order to predict the likely success of such a
treatment schedule. Second, at least under those circum-
stances where tumour cell differentiation and alteration of
epigenetic context would not be predicted to reinstate
apoptosis and no alternative mechanism exists for tumour
cell removal, sustained inactivation of the offending
oncogene would seem the desired therapeutic goal.
Results
Brief inactivation of c-Myc in islet tumours does not 
sustain tumour regression
Islet tumours were induced in nine mice by activation of
c-MycERTAM (c-Myc) in β-cells of adult pIns-c-MycERTAM
mice cross-bred with RIP7-Bcl-xL mice [22] by daily intra-
peritoneal (IP) administration of 4-OHT for 14 days as
previously described [9]. Three mice from different litters
were sacrificed for histological examination of the pan-
creas. c-Myc was then inactivated by 4-OHT withdrawal
(see Methods) for 9 days in the remaining six littermates
(two from each litter), after which time one mouse from
each litter was sacrificed for collection of pancreata and
analysis. In the remaining three mice, reactivation of c-
Myc by daily IP injection of 4-OHT was carried out for 5
days before sacrifice and analysis. For each analysis, sec-
tions (5–10µm) were cut throughout the length of the
pancreas and every tenth section was selected for histolog-
ical and immunohistochemical examination.
In the absence of 4-OHT, pIns-c-MycERTAM/RIP-Bcl-xL dou-
ble transgenic mice exhibited normal islet morphology
(Figure 1) with no measurable β-cell proliferation or
apoptosis (Figure 2). As expected, activation of c-Myc for
14 days triggered the progression of angiogenic islet
tumours (Figure 1) accompanied by β-cell proliferation,
loss of differentiation (as demonstrated by down-regula-
tion of insulin) and down-regulation of the intercellular
adhesion molecule E-cadherin (Figure 2). Following inac-
tivation of c-Myc for 9 days, histological analyses of pan-
creata showed signs of vasculature collapse particularly in
larger islets (Figure 1-extravasated erythrocytes), accom-
panied by cessation of β-cell proliferation, re-differentia-
tion (up-regulation of insulin) and reestablishment of
cell-cell contacts as E-cadherin expression was restored
(Figure 2). Vascular endothelial cell apoptosis was
detected in larger islets by co-immunostaining of vascular
basal lamina with anti-laminin antibodies together with
TUNEL (Figure 2), with only a small number of apoptotic
β-cells detected at this time-point (average of 1 cell per
islet section) following co-immunostaining of β-cells with
anti-insulin antibodies together with TUNEL (Figure 2).
Reactivation of c-Myc for 5 days in partially regressed islet
tumours (9 days of inactive c-MycERTAM) led to restora-
tion of the oncogenic properties of c-Myc (Figure 1 and 2):
β-cell proliferation, loss of differentiation (down-regula-
tion of insulin), and loss of cell-cell contacts (down-regu-
lation of E-cadherin). In contrast to the mouse model of
osteogenic sarcoma [19], where reactivation of c-Myc in
growth-arrested, re-differentiated osteocytes induced their
rapid demise through apoptosis, reactivation of c-Myc in
islet tumours did not lead to an increase in the number of
cells undergoing apoptosis compared to the original islet
tumours formed after 14 days of c-Myc activation (Figure
2). Importantly, in contrast to partially regressed islet
tumours (9 days of c-Myc inactivation), where most apop-
totic cells were found in the vasculature (Figure 2), the
majority of apoptotic cells in both the original 14-day islet
tumours and reactivated tumours were not present within
the vasculature but rather found predominantly adjacent
to blood vessels (averages of 3–4 cells per islet section c-
Myc 'on' versus 3–5 cells per islet c-Myc 'on-off-on', both
representing less than 0.1% of islet cells). A small number
of these TUNEL-positive cells could be identified as β-
cells, as deduced following co-staining with insulin (Fig-
ure 2) or Nkx6.1 (data not shown). Of the remaining
apoptotic cells, some could be identified as leukocytes by
co-staining with CD45 (data not shown). The identity of
the remainder is unclear, but could include some β-cells
with complete loss of normal differentiation markers.
Despite the presence of apoptotic cells during c-Myc acti-
vation, levels are clearly insufficient to prevent islet
tumour progression as c-Myc-induced β-cell proliferation
far exceeds apoptosis and tumours rapidly and inexorably
expand over time.
In order to establish whether islet tumour progression was
indeed being maintained following reactivation of c-Myc
we examined a longer period of c-Myc reactivation. In this
case, mice were treated daily with IP 4-OHT for 14 days
(following an initial 2 week period of c-Myc activationPage 3 of 14
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were cut throughout the pancreas and selected sections at
every 100 µm were stained with H&E for histological anal-
ysis as well as with immunohistochemical markers for
proliferation (Ki-67), differentiation (insulin), apoptosis
(TUNEL) and loss of cell-cell contact (E-cadherin). Impor-
tantly, pancreatic islets following 14 days of c-Myc reacti-
vation showed no signs of tumour regression but rather
progression of islet tumourigenesis, with the vast majority
of islets showing more pronounced invasion (adenocarci-
noma) (Figure 3).
Brief inactivation of c-Myc in papillomatous lesions of the 
skin does not sustain tumour regression
Development of papillomatosis (a pre-malignant lesion
of skin epidermis resembling actinic keratosis in humans)
was induced in nine mice following activation of c-Myc-
ERTAM (c-Myc) in suprabasal keratinocytes of adult Involu-
crin-c-MycERTAM transgenic skin by daily topical
administration of 4-OHT for 14 days as previously
described [8]. Three mice from different litters were sacri-
ficed for histological examination of the skin. c-Myc was
then inactivated by 4-OHT withdrawal (see Methods) for
Histological comparison of pancreatic islets from pIns-c-MycERTAM/Bcl-xL transgenic mice following activation, inactivation and reactivat on of c-MycERTAM (c-Myc)Figure 1
Histological comparison of pancreatic islets from pIns-c-MycERTAM/Bcl-xL transgenic mice following activation, 
inactivation and reactivation of c-MycERTAM (c-Myc). Paraffin-embedded fixed sections of pancreata from c-MycERTAM/
Bcl-xL mice were examined histologically by H&E staining. In the absence of 4-OHT (inactive c-Myc) islets exhibited normal 
morphology (Normal). Activation of c-Myc for 14 days following daily IP injection with 4-OHT induced the formation of 
hyperplastic, angiogenic islets (c-Myc on). Islets following subsequent inactivation of c-Myc for 9 days by withdrawing 4-OHT 
show evidence of vasculature collapse (c-Myc on-off). Reactivation of c-Myc for 5 days in partially regressed islets restored 
the neoplastic phenotype (c-Myc on-off-on). Scale bar: 100 µmPage 4 of 14
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litter), after which time one mouse from each litter was
sacrificed for collection of skin and analysis. In the
remaining three mice, reactivation of c-Myc by daily topi-
cal application of 4-OHT was carried out for 5 days before
sacrifice and analysis. We chose to inactivate c-Myc for 5
days in order to minimize the loss of neoplastic keratino-
cytes through outward migration and shedding from the
skin surface, prior to reactivation of c-Myc, in order to
maximise potential detection of any keratinocyte apopto-
sis. For each analysis, sections (5–10µm) were cut
throughout two 10 mm pieces of skin and every tenth sec-
tion was selected for histological and immunohistochem-
ical examination.
Immunohistochemical comparison of pancreatic islets from pIns-c-MycERTAM/Bcl-xL transgenic mice following activation, inactiva-tion a d reactivation of c-MycERTAM (c-Myc)Figure 2
Immunohistochemical comparison of pancreatic islets from pIns-c-MycERTAM/Bcl-xL transgenic mice following 
activation, inactivation and reactivation of c-MycERTAM (c-Myc). Frozen or paraffin-embedded fixed sections of pan-
creata from c-MycERTAM/Bcl-xL mice were examined immunohistochemically for the detection of: β-cell proliferation using anti-
Ki-67 antibodies; apoptosis of β-cells or vascular endothelial cells (anti-insulin (red) or anti-laminin (red) antibodies together 
with TUNEL (green). Apoptotic nuclei are highlighted with arrows; loss of cell-cell contact (anti-E-cadherin antibodies). In the 
absence of 4-OHT (inactive c-Myc) less than 0.1% of β-cells are proliferating or undergoing apoptosis (Normal). Islets from c-
MycERTAM/Bcl-xL mice following activation of c-Myc for 14 days showed a substantial degree of β-cell proliferation concomitant 
with down-regulation of insulin immuno-staining (loss of differentiation) and loss of cell-cell contact (c-Myc on). Some apop-
totic β-cells were detected but no apoptotic cells were present in the vascular endothelium. Inactivation of c-Myc for 9 days 
led to cessation of β-cell proliferation, up-regulation of insulin and E-cadherin with some vascular endothelial cell apoptosis (c-
Myc on-off). Reactivation of c-Myc for 5 days induced β-cell proliferation, down-regulation of insulin and E-cadherin (c-Myc 
on-off-on). Importantly, the same degree of apoptosis as that seen in "c-Myc on" tumours was evident. General nuclear stain: 
Dapi. Scale bar: 100 µmPage 5 of 14
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genic mice exhibited normal skin morphology (Figure 4)
with no detectable suprabasal keratinocyte proliferation
or apoptosis (Figure 5). As expected, activation of c-Myc
for 14 days triggered the progression of papillomatosis
with marked epidermal hyperplasia, dysplasia, angiogen-
esis, and formation of nucleated cornified layers (parak-
eratosis) (Figure 4). These "parakeratotic tiers" gave the
appearance of dry, scabby lesions, which were eventually
lost through lifting or flaking from the surface. The hyper-
plastic phenotype resulted from c-Myc induced prolifera-
tion of suprabasal keratinocytes, as detected using
antibodies specific for the proliferation marker Ki-67 (Fig-
ure 5). As demonstrated in our earlier studies [8], c-Myc
alone in the absence of any ectopic anti-apoptotic lesion
is sufficient to induce pre-malignant neoplastic lesions in
the skin. This contrasts with results in the pancreatic islet
β-cells, where c-Myc activation alone induces widespread
apoptosis [9]. Activation of c-Myc in the epidermis, how-
ever, is associated with essentially no detectable apoptosis
when examined by co-staining with the specific supraba-
sal keratinocyte marker keratin 1 together with TUNEL
(Figure 5). The only detectable TUNEL positive cells were
those present at the surface of the skin about to be shed
and nucleated cells within the parakeratotic tiers (Figure
5).
Subsequent inactivation of c-Myc for 5 days led to rediffer-
entiation of suprabasal keratinocytes as evidenced by the
appearance of granular cells and loss of dysplasia (Figure
4) concomitant with a marked reduction in the number of
proliferating suprabasal keratinocytes (Figure 5). Impor-
tantly, there was no increase in the number of cells under-
going apoptosis, with TUNEL positive cells again confined
to shedding keratinocytes (Figure 5), indicating that
regression of these skin lesions occurs through loss of neo-
plastic keratinocytes by shedding. Although tumour vas-
culature was examined for endothelial apoptosis, there
was no measurable increase in cell death at this particular
time-point. It is likely, however, that a more extensive
analysis would determine the particular stages at which
vascular collapse occurs following c-Myc inactivation.
Reactivation of c-Myc in skin lesions for 5 days led to res-
toration of papillomatosis (Figure 4). In contrast to the
osteogenic sarcoma model, reactivation of c-Myc in
growth arrested, redifferentiated keratinocytes did not
result in increased apoptosis, despite the absence of an
anti-apoptotic lesion (Figure 5), but again resulted in
increased levels of suprabasal proliferation extending
beyond the basal compartment (Figure 5); but as in the c-
Myc 'on', no replicating cells were present in the granular
layer. However, we cannot confirm what proportion of
Pancreatic islets from two pIns-c-MycERTAM/Bcl-xL transgenic mice following activation, inactivation, and then reactivation of c-MycERTAM (c-Myc)Figu  3
Pancreatic islets from two pIns-c-MycERTAM/Bcl-xL transgenic mice following activation, inactivation, and then 
reactivation of c-MycERTAM (c-Myc). Paraffin-embedded fixed sections of pancreata from c-MycERTAM/Bcl-xL mice were 
examined histologically by H&E staining. Activation of c-Myc for 14 days by daily IP injection with 4-OHT was followed by sub-
sequent inactivation of c-Myc for 9 days by withdrawing 4-OHT, and then reactivation of c-Myc for 14 days results in further 
progression of the neoplastic phenotype -c-Myc on-off-on (2 weeks). Extending the period of c-Myc reactivation results in 
further expansion of the tumour mass, marked dysplasia and invasion.Page 6 of 14
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BMC Biology 2004, 2:26 http://www.biomedcentral.com/1741-7007/2/26Histological comparison of skin epidermis from Involucrin-c-MycERTAM transgenic mice following activation, inactivation, and reactivat on of c-MycERTAM (c-Myc)Figure 4
Histological comparison of skin epidermis from Involucrin-c-MycERTAM transgenic mice following activation, 
inactivation, and reactivation of c-MycERTAM (c-Myc). Paraffin-embedded fixed sections of skin from Involucrin-c-MycER-
TAM mice were examined histologically by H&E staining. In the absence of 4-OHT (inactive c-Myc) the epidermis shows normal 
histology (Normal). Activation of c-Myc in skin treated topically with 4-OHT daily for 14 days induced hyperplasia, dysplasia 
and angiogenesis within papillomatous lesions (c-Myc on). Subsequent inactivation of c-Myc for 5 days following 4-OHT with-
drawal led to redifferentiation of suprabasal keratinocytes as evidenced by the appearance of the granular cells and loss of dys-
plasia (c-Myc on-off). Reactivation of c-Myc for 5 days restored the papillomatous phenotype (c-Myc on-off-on). Scale bar: 
100 µmPage 7 of 14
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reactivation, had previously experienced c-Myc activation.
This question arises as new 'c-Myc naïve' keratinocytes are
likely to have entered the suprabasal compartment as a
result of on-going basal layer replication during the tran-
sient period of c-Myc inactivation.
Discussion
The potential to inactivate or mitigate the action of onco-
genes is increasingly being exploited in the design of new
therapeutic agents to reverse tumourigenesis in cancer
therapy [1,23-25]. Importantly, despite the seeming
genetic complexity of many cancers, a compelling body of
evidence suggests that inactivation of single oncogenes
can be sufficient for tumour regression. In several trans-
genic mouse models of cancer, the generation of invasive/
metastatic tumours in which more than one genetic event
is involved can be reversed following inactivation of a sin-
gle oncogene [7,9,12,16]. In addition, c-Myc-induced
lymphomas shown to be genomically complex and unsta-
ble regressed following c-Myc inactivation [15]. Strikingly,
extensive lung metastases, arising in mice bearing Neu-
induced mammary tumours, rapidly and fully regressed
following inactivation of Neu, despite tumour cells
acquiring additional mutations [14]. These findings sug-
gest that some metastatic lesions may remain responsive
to therapeutic intervention originally targeted to the pri-
mary lesion, although some tumours have been shown to
Immunohistochemical comparison of skin epidermis from Involucrin-c-MycERTAM transgenic mice following activation, inactiva-tion, and reactivation of c-MycERTAM (c-Myc)Figure 5
Immunohistochemical comparison of skin epidermis from Involucrin-c-MycERTAM transgenic mice following 
activation, inactivation, and reactivation of c-MycERTAM (c-Myc). Frozen or paraffin-embedded fixed sections of skin 
from Involucrin-c-MycERTAM mice were examined immunohistochemically for proliferation using anti-Ki-67 antibodies, and apop-
tosis of suprabasal keratinocytes using anti-keratin 1 antibodies (red) together with TUNEL (green). In the absence of 4-OHT 
(inactive c-Myc) there were no proliferating or apoptotic keratinocytes within the suprabasal layer (Normal). Activation of c-
Myc in skin treated topically with 4-OHT daily for 14 days induced proliferation of a substantial proportion of suprabasal kerat-
inocytes (c-Myc on). The only detectable apoptotic cells were confined to shedding keratinocytes present at the surface and 
in nucleated cornified layers (parakeratosis). Inactivation of c-Myc for 5 days led to a reduction in the proportion proliferating 
suprabasal keratinocytes and no increase in the presence of apoptotic cells (c-Myc on-off). Reactivation of c-Myc for 5 days 
restored the tumour phenotype by inducing proliferation of suprabasal keratinocytes in the absence of any further apoptosis, 
TUNEL-positive cells again confined to shedding keratinocytes present at the surface and in nucleated cornified layers (c-Myc 
on-off-on). General nuclear stain: Dapi. Scale bar: 100 µmPage 8 of 14
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[6,7,11,14,16,19].
Recent data from a mouse model of osteogenic sarcoma
showed that even transient c-Myc inactivation can result
in sustained tumour regression [19]. In this model, reacti-
vation of c-Myc after a brief period of tumour regression
led to extensive apoptosis of osteoblasts rather than resto-
ration of the tumour phenotype. This increased sensitivity
to apoptosis may be due to epigenetic changes that have
occurred within the newly differentiated cells (when c-
Myc was inactivated). In light of these findings, it was
important to establish whether reactivating c-Myc in other
tumour models, consisting of other cell types, would also
lead to apoptosis. In other words, would such cells behave
differently from the original differentiated cell (in which
c-Myc was first activated) and become more sensitive to
Myc-induced apoptosis as a result of epigenetic changes?
Here we show, in contrast to the osteogenic sarcoma
model, that re-activating c-Myc in islet β-cell tumours
restores the oncogenic properties of c-Myc, rapidly re-ini-
tiating β-cell proliferation, loss of differentiation, loss of
E-cadherin, local invasion and angiogenesis. This occurs
despite the re-differentiation of previously c-Myc-acti-
vated tumour cells to a more mature phenotype and the
loss of some of the newly acquired vasculature, occurring
during the period of c-Myc inactivation. Similarly, in
epidermis, reactivating c-Myc in suprabasal keratinocytes
does not result in apoptosis, which remains confined to
the shedding areas of parakeratosis at the skin surface, but
restores the papillomatous phenotype, inducing cell pro-
liferation and dysplasia.
Self-evidently, to restore vulnerability to the pro-apop-
totic activity of c-Myc would necessitate the tumour cells
losing their resistance to apoptosis. In this case the results
of Jain et al. [19] may be explained by the origin of oste-
osarcomas in their model in bone progenitor cells, which
we assume were able to avoid c-Myc-induced apoptosis.
Subsequently, despite the retention of some features of
immaturity, these cells progress to a differentiated pheno-
type upon transient c-Myc inactivation, which renders
them susceptible to apoptosis when c-Myc is reactivated.
The assumption we must make here is that whatever
uncharacterised additional mutations these cells may
have acquired along their journey to malignancy, these
did not include mutations able to confer resistance to
apoptosis in the more mature osteocyte. One may specu-
late about the underlying mechanisms, one possibility
being the lack of a selective evolutionary advantage to
acquisition of an anti-apoptotic lesion, given that some of
these cells must already have been capable of avoiding
apoptosis – perhaps due to their primitive developmental
stage.
In our pIns-MycERTAM mice, where mature β-cells are nor-
mally highly sensitive to the pro-apoptotic activity of c-
Myc [9], invasive β-cell tumours only originate once apop-
tosis is prevented, in this case by constitutive over-expres-
sion of the protein BclxL. Without such apoptosis
suppression the majority of β-cells undergo apoptosis
upon c-Myc activation, rendering mice diabetic within a
few days. This may be one difference between our own
results and those of Jain et al. [19], namely that in our sys-
tem an acquired resistance to apoptosis is required from
the outset, but once this is in place and stays in place,
tumours develop and progress whatever the differentia-
tion status of these cells. In contrast, in the system studied
by Jain et al. [19], cells can lose their resistance to apopto-
sis whilst c-Myc is inactivated. This notion is supported by
the rapid continuation of replication and tumour growth
in our mice after a transient period of c-Myc inactivation
despite this being sufficient to restore a differentiated phe-
notype in β-cells. In contrast to the osteogenic sarcoma
model [19], it is less likely that epigenetic changes have
occurred: c-Myc is originally activated in mature islet β-
cells of the adult pancreas, and following inactivation of
c-Myc in islet tumours there is a restoration to differenti-
ated adult β-cells. Importantly, despite the beginning of
vascular collapse during c-Myc inactivation, reactivating c-
Myc appears to result not only in further growth of the
tumour, but also re-expansion of the accompanying ang-
iogenesis and more pronounced islet invasion (adenocar-
cinoma). The persistence of β-cell resistance to the pro-
apoptotic activity of c-Myc is probably conferred by the
continued presence of the anti-apoptotic protein BclxL.
Although the general consensus view is that human can-
cers largely arise from stem cells or precursor cells, it is
equally plausible that some cancers might also originate
from more mature cells. Intriguingly, recent studies in
pancreatic islets of the adult mouse suggest that putative
stem cells do not proliferate and produce new β-cells in
adult animals, but rather β-cell turnover is maintained by
proliferation of mature β-cells [26]. It is therefore quite
plausible that islet tumours might also originate from
these more mature cells, which as the major source of rep-
licating cells in the adult would also be those most likely
to acquire cancer-causing mutations. Another illuminat-
ing study from Bachoo et al. [27] shows that dysregulation
of specific genetic pathways, rather than cell-of-origin,
dictates the emergence and phenotype of high-grade
gliomas.
In order to investigate whether the absence of an anti-
apoptotic mutation would result in a shift from resistance
to apoptosis towards vulnerability following transient
inactivation of c-Myc, we examined a different mouse
tumour model. In suprabasal keratinocytes, c-Myc activa-
tion induces relentless replication leading to hyperplasia,Page 9 of 14
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actinic keratosis. In this system, differentiated suprabasal
keratinocytes presumably avoid apoptosis due to the per-
missive environment of the epidermis, as they readily
undergo apoptosis when removed from this environment
[8]. It was, however, possible that the dramatic increase in
cell numbers following c-Myc-induced epidermal hyper-
plasia might overwhelm the survival signals within this
tissue, which although sufficient to prevent any discerni-
ble apoptosis during sustained c-Myc activation might no
longer be able to prevent it after a transient inactivation
(with any accompanying restoration of normal differenti-
ation). In fact, we see no obvious change in the behaviour
of keratinocytes from before to after a period of c-Myc
inactivation. Apoptosis remains confined to the area of
parakeratosis, which accompanies c-Myc-induced hyper-
plasia and papillomatosis. At these time-points we do not
see any prominent endothelial cell apoptosis, so the exact
point at which the angiogenesis collapses is not known.
Interestingly, a recent publication suggests that following
a transient period of c-Myc inactivation, at least some
previously c-Myc activated suprabasal keratinocytes may
differentiate to an extent sufficient to render them unable
to re-enter the cell cycle after c-Myc reactivation [28]. This
is supported by our original work suggesting that more
differentiated suprabasal keratinocytes in the granular
compartment are generally refractory to c-Myc-induced
replication [8]. In this case, restoration of papillomatous
lesions in Involucrin-c-MycERTAM mice might instead result
largely from the replication of 'c-Myc naïve' keratinocytes
newly generated from the basal layer during the period of
c-Myc inactivation [28]. Whatever the underlying explana-
tion, it is difficult to be sure that all previously c-Myc acti-
vated cells have undergone irreversible growth arrest and
therefore make no contribution to restoration of the
tumour phenotype. This issue may only be resolved fully
by the development of a suitable labelling technique,
which could indelibly mark all c-Myc activated keratinoc-
ytes, but only up to the point at which c-Myc is inactivated
and not when c-Myc is reactivated.
Fortunately, with the islet model, there is no such element
of doubt. In this case no new β-cells are formed during the
period of c-Myc inactivation, with replication essentially
absent within the pancreas during this period. The replica-
tion of β-cells after c-Myc reactivation must, therefore, be
taking place in those same cells that have re-differentiated
whilst c-Myc was deactivated. Therefore, one can confi-
dently state that transient c-Myc inactivation in tumours
originating in pIns-c-MycERTAM/RIP7-Bcl-xL double trans-
genic mice will not lead to either apoptosis or irreversible
growth arrest in tumour cells. In a recently published
study, Shachaf and colleagues demonstrate in a Tet-regu-
latable conditional mouse model that invasive c-Myc-
induced hepatocellular carcinomas regress when ectopic
c-Myc expression is turned off. Importantly, by employing
a bioluminescence technique to label hepatocellular can-
cer cells, it was shown that some erstwhile tumour cells re-
differentiate but avoid apoptosis and remain 'dormant'
even for prolonged periods after c-Myc transgene expres-
sion is turned off. These labelled cells can then once more
contribute to cancer progression if c-Myc transgene expres-
sion is subsequently restored [21].
Extrapolating from these various results one may assume
that where avoidance of c-Myc induced apoptosis is a
product of cellular immaturity (as may be the case in
some stem cell populations), then as long as c-Myc inacti-
vation induces differentiation, and, presumably, no anti-
apoptotic mutation has been acquired, a transient period
may suffice for sustained tumour regression. However, in
many cases where an anti-apoptotic lesion is also present
(loss of p53/p19ARF; upregulation of antiapoptotic Bcl2
family members etc), or potentially the microenviron-
ment continues to prevent apoptosis, sustained inactiva-
tion would be essential for tumour regression. Moreover,
it can also be stated that partial reversal of angiogenesis, at
least in the islet tumours, will not have any lasting impact
on tumour progression if angiogenesis automatically con-
tinues apace of further growth of the tumour. Finally, it
seems likely that reacquisition of a differentiated pheno-
type does not preclude previously c-Myc activated cancer
cells from re-exhibiting cancer behaviour once c-Myc is
reactivated – removal of these cells by apoptosis or other
means would seem necessary to remove the threat of can-
cer recrudescence.
Identifying these key differences in behaviour between
different cell types/developmental stages is not an aca-
demic exercise, but can give vital information about the
mechanisms and context whereby oncogene activity may
be determined, which in addition to the biological
interest might also provide new knowledge of direct rele-
vance to human cancer.
Given the fact that deregulation of c-Myc expression is one
of the most frequently described abnormalities in human
cancers and has been observed in β-cell derived tumours
and in human skin epidermal tumours [29-32], our obser-
vations may have important ramifications for human can-
cers. It seems likely that therapies directed at oncogene
targets will need to be individually tailored to fit the indi-
vidual tumour types. Thus, detailed knowledge of the
molecular 'road map' to cancer for any individual tumour
would be needed before determining the optimal treat-
ment targets and therapeutic schedule. In some cases,
where describing the molecular basis of the tumour sug-
gests no inherent resistance to apoptosis, transient c-Myc
inactivation may prove an effective part of the therapeuticPage 10 of 14
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known to suppress c-Myc apoptosis would direct therapy
at maintaining sustained c-Myc inactivation. Moreover,
such detailed molecular information on the cancer cells
would have to be interpreted in the context of the relevant
microenvironments within which these cells exist. How-
ever, although we are still some distance from realising
these goals of molecular fingerprinting and individualised
therapy for cancer, the continually expanding literature
surrounding successful tumour regression with various
strategies aimed at oncogene inactivation and the knowl-
edge gained strongly suggest that the journey is worth
undertaking.
Conclusions
In several transgenic mouse models of cancer, the genera-
tion of invasive/metastatic tumours in which more than
one genetic event was involved can be reversed following
inactivation of a single oncogene. These findings suggest
that some metastatic lesions may remain responsive to
therapeutic intervention originally targeted to the primary
lesion. Recent data from a mouse model of osteogenic
sarcoma showed that even transient c-Myc inactivation
can result in sustained tumour regression [19].
Here we show the consequences of inactivating c-Myc
transiently in two distinct tumour types in vivo. In contrast
to the osteogenic sarcoma model, re-activating c-Myc in
islet β-cell tumours does not lead to accelerated β-cell
apoptosis, but rather restores the oncogenic properties of
c-Myc, rapidly re-initiating β-cell proliferation, loss of dif-
ferentiation, loss of E-cadherin, local invasion and angio-
genesis. This occurs despite the re-differentiation of
previously c-Myc-activated tumour cells to a more mature
phenotype and the loss of some of the newly acquired vas-
culature, occurring during the period of c-Myc inactiva-
tion. Similarly, in epidermis, reactivating c-Myc in
suprabasal keratinocytes does not result in apoptosis,
which remains confined to the shedding areas of parak-
eratosis at the skin surface, but restores the papillomatous
phenotype, inducing cell proliferation and dysplasia.
The differences between the conditional tumour models
used by ourselves and Jain et al. [19], rather than detract-
ing from the conclusions drawn as is frequently the case,
serve to highlight the importance of identifying different
cellular contexts in which transient inactivation of onco-
genes may provide a valid therapeutic approach. These
results are significant in that they suggest that epigenetic
changes resulting in increased sensitivity to apoptotic
stimuli will be determining the effects of altering Myc lev-
els. Although it remains to be seen whether transient inac-
tivation of other oncogenes can result in sustainable
tumour regression, these studies begin to define the
requirements necessary for transient c-Myc inactivation to
be effective as a cancer therapy. Thus, we would challenge
the potential for cancer therapies aimed at transient onco-
gene inactivation, at least under those circumstances
where tumour cell differentiation and alteration of epige-
netic context fail to reinstate apoptosis and no alternative
mechanism exists for tumour cell removal. One would
also have to be cautious about therapies that instead of
removing cancer cells might rely largely on promoting re-
differentiation – such 're-differentiated' cancer cells could
probably all too readily reacquire their cancer potential.
Together, these results suggest that treatment schedules
will need to be informed by knowledge of the molecular
basis and environmental context of any given cancer.
Methods
Transgenic mice
pIns-c-MycERTAM and Involucrin-c-MycERTAM mice were
generated by cloning a full-length human c-myc cDNA
fused to the hormone-binding domain of a modified
estrogen receptor (c-MycERTAM) downstream of the rat
insulin promoter and the human involucrin promoter,
respectively, as previously described [8,9]. DNA con-
structs were injected into male pronuclei of day 1-ferti-
lized (CBA × C57BL/6)F1 embryos and injected embryos
were transferred into day 1-plugged pseudopregnant fos-
ter mice and the litters screened for presence of the trans-
gene by Southern blotting. Heterozygous founder mice
were backcrossed appropriately to establish transgenic
lines.
Heterozygous RIP7-Bcl-xL mice were obtained from Dr
Doug Hanahan [22]. Litters from all transgenic mice and
appropriate F1 crosses were routinely genotyped by PCR
analysis on genomic DNA (1 to 5 µl) isolated from ear
biopsies. DNA was extracted by incubating each ear disc in
"Hotshot" reagent (25 mM NaOH, 0.2 mM disodium
EDTA; pH12) for 10 minutes at 95°C. Following this, 75
µl of neutralizing agent (40 mM Tris-HCl, pH5) was
added and the sample cooled to 4°C overnight. Primers
used for the detection of c-MycERTAM cDNA: (forward) 5'
CCA AAG GTT GGC AGC CCT CAT GTC 3'; (reverse) 5'
AGG GTC AAG TTG GAC AGT GTC AGA GTC 3'. PCR pro-
gram: 94°C 2 min 1 cycle, [94°C 1 min, 57°C 1 min,
72°C 2 min] 30 cycles, 72°C 10 min 1 cycle. PCR product
size: 413 bp. Primers used for the detection of RIP7-Bcl-xL
cDNA: (forward) 5' AGC ACT TTC TGC AGA CCT AGC AC
3'; (reverse) 5' CAG CTC CCG GTT GCT CTG AGA C 3'.
PCR program: [94°C 1 min, 60°C 30 s, 72°C 2 min] 30
cycles, 72°C 3 min 1 cycle.
Transgenic mice were housed under barrier conditions
with a 12 hour light/dark cycle and access to food and
water ad libitum.Page 11 of 14
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Expression of the chimeric protein, c-MycERTAM, was tar-
geted to pancreatic β-cells using a rat insulin promoter, or
to suprabasal keratinocytes using the human involucrin
promoter. As shown in our previous publications [8,9],
the transgenically expressed c-MycERTAM protein remains
inactive due to association of the cells' own hsp90 with
the ERTAM. Upon administration of 4-hydroxytamoxifen
(4-OHT), hsp90 is displaced allowing association of c-
Myc's partner, Max, to form transcriptionally active het-
erodimers [33].
To activate c-MycERTAM protein in pancreatic β-cells of
adult transgenic mice, 1 mg of 4-OHT (Sigma) sonicated
in peanut oil (1 mg/0.2 ml) was administered daily by IP
injection. To activate c-MycERTAM protein in skin epider-
mis of adult transgenic mice, 1 mg of 4-OHT (Sigma) dis-
solved in ethanol (1 mg/0.2 ml) was administered daily
by topical application to a shaved area of dorsal skin.
Inactivation of c-MycERTAM protein was achieved follow-
ing withdrawal of 4OHT. As c-MycERTAM RNA and protein
levels remain unchanged in the presence or absence of
4OHT, Northern and Western blot analysis will not con-
firm whether the protein is inactive. Thus, to confirm
inactivity of the c-MycERTAM protein in pancreatic β-cells,
we show reversal of several markers of Myc activation by
day 4 of 4OHT withdrawal -growth arrest, re-differentia-
tion, re-establishment of cell-cell contact – by immuno-
histochemistry (see ref [9] and Results section). In
addition, we have gene array data confirming the rapid
normalisation of Myc-regulated gene expression, of
tamoxifen withdrawal (eg. insulin, pdx-1, Isl-1, cyclin D;
data not shown).
Similarly, inactivation of c-MycERTAM protein in skin epi-
dermis was confirmed using immunohistochemistry for
markers of re-differentiation (K1 and K14) and growth
arrest (see Results section). The tight regulation of the c-
MycERTAM protein in skin epidermis was also previously
shown in [8] using in situ hybridisation for detection of
ODC RNA, a known c-Myc target gene; by day 5 following
withdrawal of 4OHT, ODC RNA is no longer detected.
Histological and immunohistochemical analysis of 
pancreatic tissue
Pancreata or skin were excised from mice and 5–10 mm
pieces of tissue were fixed overnight in neutral-buffered
formalin, embedded in paraffin wax and sectioned (5–10
µm). Frozen sections were prepared from tissue embed-
ded in OCT and frozen in foil on a bath of dry ice and eth-
anol. Prior to staining, frozen sections were air-dried and
fixed in 4% paraformaldehyde for 15 minutes. Alterna-
tively, for frozen sections, tissue was fixed in 4% parafor-
maldehyde for 2 hours followed by incubation in 30%
sucrose overnight at 4°C. For pancreata analysis, sections
(5–10µm) were cut throughout the entire pancreas and
every tenth section was selected for histological and
immunohistochemical examination. For skin, sections
(5–10µm) were cut through two 10 mm pieces of tissue
and every tenth section was selected for analysis.
Primary antibodies were as follows: rabbit polyclonals Ki-
67 (Novacastra) and Nkx6.1 (Ole Madsen, NovoNord-
isk); rabbit anti-mouse laminin (Sigma); guinea-pig anti-
porcine insulin (Dako); rat anti-mouse E-cadherin,
(Zymed); rabbit anti-mouse keratin 1 (BabCo); rat anti-
mouse CD45 (AbCam). E-cadherin and laminin antibod-
ies were found to label reliably only frozen tissue sections.
Other antibodies were effective when used on both paraf-
fin-embedded and frozen sections, although Ki-67 and
Nkx6.1 required epitope retrieval by microwaving paraf-
fin-embedded sections at 700 W for 2 × 10 minutes in
0.01 M citrate buffer, pH6.0 (Vector) followed by immer-
sion in cold water.
Antibodies were diluted in incubation buffer: PBS/0.5%
Triton X-100 containing 1:25 dilution of serum from the
same species as the secondary antibody. Primary antibod-
ies for insulin and Ki-67 were applied together to sections
for 1 hour. Sections were then incubated in Texas Red-
conjugated goat anti-guinea pig Ig secondary antibody
together with FITC-conjugated goat anti-rabbit secondary
antibody (Vector). After washing, sections were mounted
in Vectashield mounting medium (Vector).
To detect cells undergoing apoptosis, costaining with
TUNEL/insulin, TUNEL/laminin and TUNEL/K1, immun-
ofluorescent staining was performed by applying insulin,
laminin or K1 antibodies to sections for 1 hour at room
temperature followed by Texas Red-conjugated goat anti-
guinea pig (for insulin antibodies) and goat anti-rabbit
(for laminin and K1 antibodies) Ig secondary antibody
(Vector). TUNEL staining was subsequently performed
using ApopTag Fluorescein Direct kit (Chemicon) for fro-
zen tissue sections and ApopTag Fluorescein Indirect kit
(Chemicon) for paraffin-embedded tissue sections.
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